EcoDrugPlus

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSCSEG00000011383
Gene Symbol: PSMA2
3 Cross references
278 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSCSEG00000011909
Gene Symbol: PSMA3
3 Cross references
252 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSCSEG00000012634
Gene Symbol: PSMA4
4 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSCSEG00000004690
Gene Symbol: PSMA5
3 Cross references
212 Possible Orthologues:

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSCSEG00000019100
Gene Symbol: PSMA6
3 Cross references
262 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSCSEG00000011339
Gene Symbol: PSMA8
3 Cross references
183 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSCSEG00000000258
Gene Symbol: PSMB1
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSCSEG00000010643
Gene Symbol: PSMB2
3 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSCSEG00000016289
Gene Symbol: PSMB3
3 Cross references
261 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSCSEG00000019568
Gene Symbol: PSMB4
3 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSCSEG00000005875
Gene Symbol: PSMB6
3 Cross references
228 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSCSEG00000019199
Gene Symbol: PSMB8
3 Cross references
220 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).